- Nano cap Anthera Pharmaceuticals (OTC:ANTH) is set for an ugly day after announcing that lead candidate Sollpura failed to demonstrate non-inferiority to Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals' PANCREAZE (pancrelipase) in a Phase 3 study.
- The study, RESULT, failed to achieve the primary endpoint of an improvement in coefficient of fat absorption (CFA) from baseline within the 95% non-inferiority margin.
- The study did achieve the secondary endpoint of coefficient of nitrogen absorption (CNA).
- The company says it will terminate further development.
- Shares, currently halted, will resume trading at 8:30 am ET.
- Management will host a conference call at 8:30 am ET to discuss the results.
Anthera to terminate development of Sollpura after failed late-stage study
This was corrected on 02/06/2019 at 10:26 AM. Secondary endpoint met.
Recommended For You
About ANTH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ANTH | - | - |
Anthera Pharmaceuticals, Inc. |